Alvotech (NASDAQ:ALVO - Get Free Report) is anticipated to issue its quarterly earnings data after the market closes on Wednesday, March 26th. Analysts expect the company to announce earnings of ($0.74) per share and revenue of $97.99 million for the quarter. Parties interested in registering for the company's conference call can do so using this link.
Alvotech Trading Up 0.2 %
NASDAQ ALVO traded up $0.02 on Friday, hitting $11.57. 233,864 shares of the company were exchanged, compared to its average volume of 137,014. The company has a market cap of $3.49 billion, a PE ratio of -6.25 and a beta of -0.16. Alvotech has a 12 month low of $9.15 and a 12 month high of $15.04. The stock has a fifty day moving average of $12.20 and a 200-day moving average of $12.16.
Analyst Ratings Changes
Separately, UBS Group initiated coverage on shares of Alvotech in a research note on Friday, February 14th. They set a "buy" rating and a $18.00 target price on the stock.
Get Our Latest Analysis on ALVO
Alvotech Company Profile
(
Get Free Report)
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass.
Featured Stories
Before you consider Alvotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alvotech wasn't on the list.
While Alvotech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
